Circulating monocytes and tumor‐associated macrophages express recombined immunoglobulins in glioblastoma patients

• DOI: 10.1186/s40169-019-0235-8
• Publication Date: 2019-06-02T23:02:27Z
• Authors: Svenja Busch; Marina Talamini; Steffen Brenner; Amr Abdulazim; Daniel Hänggi; Michael Neumaier; Marcel Seiz‐Rosen...; Tina Fuchs
• Keywords: Monocyte; Immunoglobulin heavy chain; Tumor progression

Abstract Background Glioblastoma is the most common and malignant brain tumor in adults. usually fatal 12–15 months after diagnosis current possibilities therapy are mostly only palliative. Therefore, new forms of urgently needed. Since tumor‐associated macrophages key players progression survival there large potential investigating their immunological characteristics glioblastoma patients. Recent evidence shows expression variable immunoglobulins TCRαβ subpopulations monocytes, vitro polarized microenvironment. We set out to investigate immunoglobulin sequences circulating monocytes from patients evaluate as novel diagnostic or therapeutic targets. Results routinely find consistent (TAM) all analyzed this study. However, repertoires TAM generally more restricted compared B cells. Furthermore, macrophage populations negatively correlates with volume. Interestingly, comparison somatic mutations, V‐chain usage, CDR3‐length distribution used heavy chain genes on locus chromosome 14 myeloid cells revealed virtually no differences. Conclusions The investigation glioblastoma‐patients a negative correlation volume, which could not be detected patients’ lymphocytes. were diverse than microenvironment same suggesting tumor‐specific immune response advantageous for use target.